Abstract: The present invention relates to pharmaceutical formulations for heterodimeric Fc-fused proteins which are advantageous for achieving higher titers of the proteins during production, higher stability during storage, and improved efficacy when used as a therapeutic. Also provided are dosage regimens for such heterodimeric Fc-fused proteins and pharmaceutical formulations for use in treating cancer, such as locally advanced or metastatic solid tumor.

Abstract: Multispecific binding proteins that bind NKG2D receptor, CD16, and 5T4 are described, as well as pharmaceutical compositions, formulations, and therapeutic methods of the multispecific binding proteins useful for the treatment of cancer.

Abstract: Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies.

Abstract: Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies.

Abstract: Multi-specific binding proteins that bind the NKG2D receptor, CD 16, and a tumor-associated antigen on tumor cells, or an antigen on myeloid-derived suppressor cells or tumor-associated macrophages are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.